• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Warrant (NQ:NAMSW)

20.26 -3.69 (-15.41%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NewAmsterdam Pharma Company N.V. - Warrant

< Previous 1 2 3 Next >
News headline image
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
January 09, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2026
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
November 25, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 07, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
November 05, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
October 30, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
September 24, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
August 25, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
August 18, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 06, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
July 30, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
July 22, 2025
– NewAmsterdam to host conference call at 10:00 a.m. ET on Wednesday, July 30th – 
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
June 09, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
June 05, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
May 27, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
May 14, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
May 08, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
May 07, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
April 30, 2025
Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers 
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
April 17, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
February 26, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
February 25, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
January 29, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
January 10, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 09, 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
December 13, 2024
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap